Despite the fact that Hodgkin’s lymphoma (HL) patients generally have very high cure rates of 70%-90% with frontline multi-agent chemotherapies, the battle against this hematological malignancy is still ongoing.1,2 About 20% of HL patients were found failure to stay in complete remission (CR) within a year after the initial frontline therapies, and required autologous hematopoietic stem cell transplantation (HSCT) for the improvement of long-term outcomes.1 Yet, autologous HSCT could only cure 50% of the high-risk patients, meaning that half of them still experience progressive disease after autologous HSCT.2 Enormous efforts have been made to address the unmet medical needs of these patients since the 1990s, but a breakthrough only came in 2015 when brentuximab vedotin (BV) was investigated and shown to be highly efficacious in consolidating CR among high-risk HL patients who had undergone autologous HSCT.2 In an interview with Omnihealth Practice, Dr. Chan, Hiu-Yan Kitty discussed the unmet medical needs of HL patients and presented a case to demonstrate the clinical benefits of BV consolidation therapy in the local clinical setting.
